Skip to main content

Table 2 Possible treatments in both trial arms

From: Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial

Arm 1: apixaban

Arm 2: avoid anticoagulation

Apixaban 5 mg twice daily

No antithrombotic treatment

Apixaban 2.5 mg twice dailya

Acetylsalicylic acid 80 mg once daily

 

Carbasalate calcium 100 mg once daily

 

Clopidogrel 75 mg once daily

 

Acetylsalicylic acid 80 mg once daily and dipyridamole 200 mg twice daily

 

Carbasalate calcium 100 mg once daily and dipyridamole 200 mg twice daily

  1. aReduced dose: the dose will be reduced if 2 of the 3 following criteria are met: age ≥ 80 years, body weight ≤ 60 kg or serum creatinine ≥133 μmol. If the creatinine clearance is below 30 ml per minute, the dose will also be reduced